Clinical Infrastructure & Trial Opportunities in the Norwegian Radiopharma & Theranostics Ecosystem
Norway offers a solid foundation for radiopharmaceutical and theranostics clinical trials, with well-established clinical expertise, access to patients, and advanced infrastructure. However, these strengths are not always well connected or clearly presented across the national ecosystem.
Oslo Cancer Cluster and the National Expert Group for Radiotherapy Research (NERR) are hosting an upcoming meeting that brings together hospitals, clinical researchers, emerging radiopharma companies, global pharma, and ecosystem partners. The goal is to share ongoing initiatives, learn from international examples, and identify gaps and opportunities The event is the first in a meeting series, and ties into a broader Norwegian theranostic initiative coordinated by Caroline (OUS/UiO).
The aim is to position Norway as a preferred destination for radiopharmaceutical trials. The programme features an international keynote by Prof. Frederik Giesel (University Hospital Düsseldorf), presentations from leading Norwegian clinical and research environments, and perspectives from industry on how to strengthen collaboration and accelerate clinical development.